Thymectomy Improves Outcomes in Non-Thymomatous Myasthenia Gravis Thymectomy Improves Outcomes in Non-Thymomatous Myasthenia Gravis
Thymectomy plus prednisone improves outcomes in patients with non-thymomatous myasthenia gravis (MG), compared with prednisone alone, according to results from the two-year extension of the MGTX randomized trial.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - February 6, 2019 Category: Allergy & Immunology Tags: Neurology & Neurosurgery News Source Type: news
Thymectomy & #43; PDN Beneficial for Non-Thymomatous Myasthenia Gravis
WEDNESDAY, Jan. 30, 2019 -- For patients with non-thymomatous myasthenia gravis, thymectomy plus prednisone confers benefits versus prednisone alone at five years, according to a study published online Jan. 25 in The Lancet Neurology.
Gil I. Wolfe,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 30, 2019 Category: Pharmaceuticals Source Type: news
When You ’ re Struggling with Self-Loathing in Bipolar Disorder
Many people with bipolar disorder struggle with self-loathing. Maybe the self-loathing starts as the depressive phase does with all sorts of awful thoughts about yourself. Because that’s how depression works: It outright lies, and inflicts pain.
You can’t do anything right. You’re an abject failure. You’re also stupid. And worthless, and no one will ever really love you for you. You are not attractive or thin or strong enough. You are weak, and you are an embarrassment.
Maybe it happens after a manic or hypomanic episode, because you feel terrible about what you did or said during that time. And the regret, rem...
Source: Psych Central - December 2, 2018 Category: Psychiatry Authors: Margarita Tartakovsky, M.S. Tags: Bipolar Disorders General Self-Esteem Self-Help Autoimmune Disease Bipolar Disorder Mood Disorder Negative Thoughts Self Hatred Self Loathing Source Type: news
FDA OKs First Treatment for Lambert-Eaton Myasthenic Syndrome FDA OKs First Treatment for Lambert-Eaton Myasthenic Syndrome
Amifampridine (Firdapse) is approved for adults with Lambert-Eaton myasthenic syndrome, a rare autoimmune disorder characterized by muscle weakness.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 30, 2018 Category: Consumer Health News Tags: Neurology & Neurosurgery News Alert Source Type: news
FDA approves first treatment for Lambert-Eaton myasthenic syndrome, a rare autoimmune disorder
The U.S. Food and Drug Administration today approved Firdapse (amifampridine) tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. LEMS is a rare autoimmune disorder that affects the connection between nerves and muscles and causes weakness and other symptoms in affected patients. This is the first FDA approval of a treatment for LEMS. (Source: World Pharma News)
Source: World Pharma News - November 30, 2018 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news
Immune checkpoints could be key to treating autoimmune disease myasthenia gravis
(Kanazawa University) The PD-1 immune checkpoint is essential for self-recognition by the immune system, with disruption of the pathway associated with several autoimmune disorders. However, the involvement of PD-1 and its ligand PD-L1 in muscle-weakening autoimmune disease myasthenia gravis is unclear. Now, researchers at Kanazawa University have linked increased PD-L1 expression in the muscles of myasthenia gravis patients with disease severity and shown that this could ultimately help control the immune response and modulate disease symptoms. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 30, 2018 Category: International Medicine & Public Health Source Type: news
FDA Approves Firdapse for Rare Autoimmune Disorder
First agency - sanctioned treatment for adults with Lambert - Eaton myasthenic syndrome (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - November 30, 2018 Category: Cancer & Oncology Tags: Neurology, Oncology, Pharmacy, Institutional, Source Type: news
FDA Approves Firdapse for Rare Autoimmune Disorder
THURSDAY, Nov. 29, 2018 -- Firdapse (amifampridine) tablets have been approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton myasthenic syndrome (LEMS).
The drug is the first agency-sanctioned treatment for the autoimmune... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 29, 2018 Category: Pharmaceuticals Source Type: news
FDA approves new drug developed by Coral Gables company
The U.S. Food and Drug Administration has approved Firdapse, a new medicine developed by Coral Gables-based Catalyst Pharmaceuticals.
The biopharmaceutical company (Nasdaq: CPRX) expects the drug to be commercially available in the first quarter of 2019. It was designed to treat Lambert-Eaton Myasthenic Syndrome, a rare autoimmune disease that causes muscle weakness and fatigue.
"The approval of Firdapse is a crowning achieveme nt for our company and an important step forward in our transition into… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - November 29, 2018 Category: Biotechnology Authors: Emon Reiser Source Type: news
Firdapse (Amifampridine) Approved for Rare Autoimmune Disorder
THURSDAY, Nov. 29, 2018 -- Firdapse (amifampridine) tablets have been approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton myasthenic syndrome (LEMS).
It ' s the first agency-sanctioned treatment for the autoimmune disease... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - November 29, 2018 Category: General Medicine Source Type: news
FDA Approves Firdapse (amifampridine) for Lambert-Eaton Myasthenic Syndrome
November 28, 2018 -- The U.S. Food and Drug Administration today approved Firdapse (amifampridine) tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. LEMS is a rare autoimmune disorder that affects the connection... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 28, 2018 Category: Drugs & Pharmacology Source Type: news
FDA approves first treatment for Lambert-Eaton myasthenic syndrome, a rare autoimmune disorder
FDA approved Firdapse (amifampridine) tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. LEMS is a rare autoimmune disorder. This is the first FDA approval of a treatment for LEMS. (Source: Food and Drug Administration)
Source: Food and Drug Administration - November 28, 2018 Category: American Health Source Type: news
Catalyst Pharmaceuticals files new drug application with FDA
Catalyst Pharmaceuticals has submitted a new drug application (NDA) to the U.S. Food and Drug Administration, bringing the Coral Gables-based drug maker one step closer to launching Firdapse, a treatment for a rare degenerative neuromuscular disease.
Founded in 2002, Catalyst (Nasdaq: CPRX) has been working to develop Firdapse for almost a decade, a common timeline in the highly regulated pharmaceutical industry.
Firdapse aims to treats symptoms of Lambert-Eaton myasthenic syndrome, a degenerative… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - March 29, 2018 Category: Health Management Authors: Debora Lima Source Type: news
Catalyst Pharmaceuticals Announces Submission of New Drug Application for Firdapse for Treatment of Lambert-Eaton Myasthenic Syndrome
CORAL GABLES, Fla., March 29, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - March 29, 2018 Category: Drugs & Pharmacology Source Type: news
What is the Besinger Score?
Discussion
Myasthenia gravis (MG) is a rare disease in the pediatric population. The incidence depends on the population studied but is estimated at 1-9/1 million/year. It was first described by William Heinrich Erb in 1879. The cause is autoantibodies against components of the post-synaptic membrane of the neuromuscular junction, usually against the acetylcholine binding receptor (AChR).
It can occur at any age but is more common in the adult population. Juvenile patients (0-19 years) are divided into prepubertal (12 years) who have disease presentations similar to the adult population. In adults there are 5 grades: ocula...
Source: PediatricEducation.org - February 19, 2018 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news
